Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Noonan, 2008, Inflammation, inflammatory cells and angiogenesis: decisions and indecisions, Cancer Metastasis Rev, 27, 31, 10.1007/s10555-007-9108-5 Palucka, 2016, The basis of oncoimmunology, Cell, 164, 1233, 10.1016/j.cell.2016.01.049 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Liang, 2016, The complex role of neutrophils in tumor angiogenesis and metastasis, Cancer Immunol Res, 4, 83, 10.1158/2326-6066.CIR-15-0313 Sica, 2015, Macrophage polarization in pathology, Cell Mol Life Sci, 72, 4111, 10.1007/s00018-015-1995-y Kitamura, 2015, Immune cell promotion of metastasis, Nat Rev Immunol, 15, 73, 10.1038/nri3789 Ruffell, 2015, Macrophages and therapeutic resistance in cancer, Cancer Cell, 27, 462, 10.1016/j.ccell.2015.02.015 Strauss, 2015, RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis, Cancer Cell, 28, 253, 10.1016/j.ccell.2015.07.006 Lewis, 2016, The multifaceted role of perivascular macrophages in tumors, Cancer Cell, 30, 18, 10.1016/j.ccell.2016.05.017 Hughes, 2015, Perivascular M2 macrophages stimulate tumor relapse after chemotherapy, Cancer Res, 75, 3479, 10.1158/0008-5472.CAN-14-3587 Teresa Pinto, 2016, Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities, Sci Rep, 6, 18765, 10.1038/srep18765 Lin, 2015, CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer, Oncotarget, 6, 34758, 10.18632/oncotarget.5325 Yeo, 2014, Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer, Cancer Res, 74, 2962, 10.1158/0008-5472.CAN-13-2421 Vinnakota, 2017, M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases, J Cell Physiol, 10.1002/jcp.25808 Deryugina, 2010, Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions, Biochim Biophys Acta, 1803, 103, 10.1016/j.bbamcr.2009.09.017 Kurahara, 2013, M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer, Pancreas, 42, 155, 10.1097/MPA.0b013e318254f2d1 Spiric, 2015, Significance of vascular endothelial growth factor (VEGF)-C and VEGF-D in the progression of cutaneous melanoma, Int J Surg Pathol, 23, 629, 10.1177/1066896915583694 Ji, 2014, TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling, Nat Commun, 5, 4944, 10.1038/ncomms5944 Yang, 2015, Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway, Med Oncol, 32, 352, 10.1007/s12032-014-0352-6 Chung, 2012, Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer, Int J Cancer, 131, E227, 10.1002/ijc.27403 Gabrilovich, 2017, Myeloid-derived suppressor cells, Cancer Immunol Res, 5, 3, 10.1158/2326-6066.CIR-16-0297 Bronte, 2016, Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards, Nat Commun, 7, 12150, 10.1038/ncomms12150 Mandruzzato, 2016, Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study, Cancer Immunol Immunother, 65, 161, 10.1007/s00262-015-1782-5 Condamine, 2015, Transcriptional regulation of myeloid-derived suppressor cells, J Leukoc Biol, 98, 913, 10.1189/jlb.4RI0515-204R Messmer, 2015, Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy, Cancer Immunol Immunother, 64, 1, 10.1007/s00262-014-1639-3 Solito, 2014, Myeloid-derived suppressor cell heterogeneity in human cancers, Ann N Y Acad Sci, 1319, 47, 10.1111/nyas.12469 Zhang, 2016, The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis, PLOS ONE, 11, e0164514, 10.1371/journal.pone.0164514 Kumar, 2016, The nature of myeloid-derived suppressor cells in the tumor microenvironment, Trends Immunol, 37, 208, 10.1016/j.it.2016.01.004 Hoechst, 2011, Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells, Blood, 117, 6532, 10.1182/blood-2010-11-317321 Hoechst, 2009, Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor, Hepatology, 50, 799, 10.1002/hep.23054 Kumar, 2016, CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation, Immunity, 44, 303, 10.1016/j.immuni.2016.01.014 Yang, 2004, Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer Cell, 6, 409, 10.1016/j.ccr.2004.08.031 Shaul, 2017, Neutrophils as active regulators of the immune system in the tumor microenvironment, J Leukoc Biol, 10.1189/jlb.5MR1216-508R Andzinski, 2016, Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human, Int J Cancer, 138, 1982, 10.1002/ijc.29945 Donskov, 2013, Immunomonitoring and prognostic relevance of neutrophils in clinical trials, Semin Cancer Biol, 23, 200, 10.1016/j.semcancer.2013.02.001 Cools-Lartigue, 2013, Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis, J Clin Invest, 10.1172/JCI67484 Deryugina, 2014, Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment, Neoplasia, 16, 771, 10.1016/j.neo.2014.08.013 Tecchio, 2014, Neutrophil-derived cytokines involved in physiological and pathological angiogenesis, Chem Immunol Allergy, 99, 123, 10.1159/000353358 Mishalian, 2014, Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17—a new mechanism of impaired antitumor immunity, Int J Cancer, 135, 1178, 10.1002/ijc.28770 Dumitru, 2013, Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression, Semin Cancer Biol, 23, 141, 10.1016/j.semcancer.2013.02.005 Sudam Patil, 2016, IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients, Int J Cancer, 139, 869, 10.1002/ijc.30134 Terme, 2013, VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer, Cancer Res, 73, 539, 10.1158/0008-5472.CAN-12-2325 Donini, 2015, Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg), Target Oncol, 10, 277, 10.1007/s11523-014-0337-6 Carrega, 2016, The Yin and Yang of innate lymphoid cells in cancer, Immunol Lett, 179, 29, 10.1016/j.imlet.2016.06.003 Montaldo, 2016, Human innate lymphoid cells, Immunol Lett, 179, 2, 10.1016/j.imlet.2016.01.007 Vallentin, 2015, Innate lymphoid cells in cancer, Cancer Immunol Res, 3, 1109, 10.1158/2326-6066.CIR-15-0222 Bruno, 2014, A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis, J Natl Cancer Inst, 106, 10.1093/jnci/dju200 Bruno, 2014, Orchestration of angiogenesis by immune cells, Front Oncol, 4, 131, 10.3389/fonc.2014.00131 Remark, 2013, Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin, Clin Cancer Res, 19, 4079, 10.1158/1078-0432.CCR-12-3847 Bruno, 2013, The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer, Neoplasia, 15, 133, 10.1593/neo.121758 Morandi, 2015, CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation, J Immunol, 195, 965, 10.4049/jimmunol.1500591 Mattner, 2017, Friend or foe? The ambiguous role of innate lymphoid cells in cancer development, Trends Immunol, 38, 29, 10.1016/j.it.2016.10.004 Monticelli, 2015, IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions, Proc Natl Acad Sci U S A, 112, 10762, 10.1073/pnas.1509070112 Zaiss, 2013, Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor, Immunity, 38, 275, 10.1016/j.immuni.2012.09.023 Geremia, 2011, IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease, J Exp Med, 208, 1127, 10.1084/jem.20101712 Kirchberger, 2013, Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model, J Exp Med, 210, 917, 10.1084/jem.20122308 Pan, 2015, Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer, Sci Rep, 5, 16053, 10.1038/srep16053 Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 Gabrilovich, 1999, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, 5, 2963 Dirkx, 2003, Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression, Cancer Res, 63, 2322 Gordon, 2016, The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation, Sci Signal, 9, ra72, 10.1126/scisignal.aad9256 Schonle, 2016, Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells, Blood, 127, 1930, 10.1182/blood-2015-09-672428 Hodi, 2014, Bevacizumab plus ipilimumab in patients with metastatic melanoma, Cancer Immunol Res, 2, 632, 10.1158/2326-6066.CIR-14-0053 Huang, 2015, VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation, FASEB J, 29, 227, 10.1096/fj.14-250985 Wu, 2016, VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma, Cancer Immunol Res, 4, 858, 10.1158/2326-6066.CIR-16-0084 Wu, 2017, Combined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes, Cancer Immunol Res, 5, 446, 10.1158/2326-6066.CIR-16-0385 Allen, 2017, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation, Sci Transl Med, 9, 10.1126/scitranslmed.aak9679 Schmittnaegel, 2017, Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade, Sci Transl Med, 9, 10.1126/scitranslmed.aak9670 Pyonteck, 2013, CSF-1R inhibition alters macrophage polarization and blocks glioma progression, Nat Med, 19, 1264, 10.1038/nm.3337 Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016 Albini, 2009, Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target, J Transl Med, 7, 5, 10.1186/1479-5876-7-5 Acquati, 2011, Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase, Proc Natl Acad Sci U S A, 108, 1104, 10.1073/pnas.1013746108 Baer, 2016, Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity, Nat Cell Biol, 18, 790, 10.1038/ncb3371 Brahmi, 2016, Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis, Curr Treat Options Oncol, 17, 10, 10.1007/s11864-015-0385-x Butowski, 2016, Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study, Neuro Oncol, 18, 557, 10.1093/neuonc/nov245 Brana, 2015, Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study, Target Oncol, 10, 111, 10.1007/s11523-014-0320-2 Pienta, 2013, Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, Invest New Drugs, 31, 760, 10.1007/s10637-012-9869-8 Sandhu, 2013, A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors, Cancer Chemother Pharmacol, 71, 1041, 10.1007/s00280-013-2099-8 Papadopoulos, 2016, A phase I first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors, Clin Cancer Res, 22, 1348, 10.1158/1078-0432.CCR-15-1221 Allavena, 2013, Trabectedin: a drug from the sea that strikes tumor-associated macrophages, Oncoimmunology, 2, e24614, 10.4161/onci.24614 Germano, 2013, Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, 23, 249, 10.1016/j.ccr.2013.01.008 Dossi, 2015, Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1, Int J Cancer, 136, 721 Ramachandran, 2016, Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy, Cancer Lett, 371, 117, 10.1016/j.canlet.2015.10.040 Vetsika, 2014, A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients, J Immunol Res, 2014, 659294, 10.1155/2014/659294 Meyer, 2014, Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer Immunol Immunother, 63, 247, 10.1007/s00262-013-1508-5 Tarhini, 2014, Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab, PLOS ONE, 9, e87705, 10.1371/journal.pone.0087705 Highfill, 2014, Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy, Sci Transl Med, 6, 237ra267, 10.1126/scitranslmed.3007974 Weber, 2016, Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab, Cancer Immunol Res, 4, 345, 10.1158/2326-6066.CIR-15-0193 Iclozan, 2013, Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer, Cancer Immunol Immunother, 62, 909, 10.1007/s00262-013-1396-8 Condamine, 2014, ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis, J Clin Invest, 124, 2626, 10.1172/JCI74056 Galluzzi, 2016, Immunological mechanisms underneath the efficacy of cancer therapy, Cancer Immunol Res, 4, 895, 10.1158/2326-6066.CIR-16-0197 He, 2013, Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation, J Transl Med, 11, 186, 10.1186/1479-5876-11-186 Xu, 2013, Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1, Cancer Immunol Immunother, 62, 1637, 10.1007/s00262-013-1466-y Albini, 2012, Cancer prevention by targeting angiogenesis, Nat Rev Clin Oncol, 9, 498, 10.1038/nrclinonc.2012.120 Derlindati, 2012, Quercetin-3-O-glucuronide affects the gene expression profile of M1 and M2a human macrophages exhibiting anti-inflammatory effects, Food Funct, 3, 1144, 10.1039/c2fo30127j